Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Podzamczer

Showing results (31-40 of 181) with videos related to

Pageof 19
Sort By:
AIDS (London, England)|July 29, 2004
Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or lessElena Ferrer, Elena Santamariña, Pere Domingo, et al.
AIDS (London, England)|March 19, 2015
Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patientsEva Van den Eynde, Jordi Curto, Elena Ferrer, et al.
Current HIV Research|June 9, 2022
Short-term Neuropsychiatric and Body Weight Changes in Patients Switching From EVG/Cobi/FTC/TAF to BIC/FTC/TAF (PreEC/RIS69)Juan Tiraboschi, Paula Prieto, Maria Saumoy, et al.
Antiviral Therapy|January 18, 2005
Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapyXavier Badía, Daniel Podzamczer, Irene Moral, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|July 25, 2021
Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention?Maria Jesús Pérez-Elías, Daniel Podzamczer Palter, Pere Ventayol Bosch, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|July 4, 2021
Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention?Maria Jesús Pérez-Elías, Daniel Podzamczer Palter, Pere Ventayol Bosch, et al.
HIV Clinical Trials|January 14, 2017
Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudyMaria Saumoy, Juan M Tiraboschi, Jordi Ordoñez-Llanos, et al.
The Journal of Antimicrobial Chemotherapy|September 28, 2015
Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline statusElena Ferrer, Jordi Curto, Anna Esteve, et al.
BMC Infectious Diseases|June 27, 2015
Prevalence of methicillin-resistant Staphylococcus aureus colonization in HIV-infected patients in Barcelona, Spain: a cross-sectional studyArkaitz Imaz, Mariana Camoez, Silvana Di Yacovo, et al.
Antiviral Therapy|March 9, 2005
Early virological failure with a combination of tenofovir, didanosine and efavirenzDaniel Podzamczer, Elena Ferrer, Josep Maria Gatell, et al.
Pageof 19

Showing results (31-40 of 181) with videos related to

Sort By:
Pageof 19
AIDS (London, England)|July 29, 2004
Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or lessElena Ferrer, Elena Santamariña, Pere Domingo, et al.
AIDS (London, England)|March 19, 2015
Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patientsEva Van den Eynde, Jordi Curto, Elena Ferrer, et al.
Current HIV Research|June 9, 2022
Short-term Neuropsychiatric and Body Weight Changes in Patients Switching From EVG/Cobi/FTC/TAF to BIC/FTC/TAF (PreEC/RIS69)Juan Tiraboschi, Paula Prieto, Maria Saumoy, et al.
Antiviral Therapy|January 18, 2005
Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapyXavier Badía, Daniel Podzamczer, Irene Moral, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|July 25, 2021
Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention?Maria Jesús Pérez-Elías, Daniel Podzamczer Palter, Pere Ventayol Bosch, et al.
Enfermedades Infecciosas Y Microbiologia Clinica (English Ed.)|July 4, 2021
Clinical and economic benefit of 32 years of antiretroviral treatment for people living with HIV in Spain: Has it been an efficient intervention?Maria Jesús Pérez-Elías, Daniel Podzamczer Palter, Pere Ventayol Bosch, et al.
HIV Clinical Trials|January 14, 2017
Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudyMaria Saumoy, Juan M Tiraboschi, Jordi Ordoñez-Llanos, et al.
The Journal of Antimicrobial Chemotherapy|September 28, 2015
Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline statusElena Ferrer, Jordi Curto, Anna Esteve, et al.
BMC Infectious Diseases|June 27, 2015
Prevalence of methicillin-resistant Staphylococcus aureus colonization in HIV-infected patients in Barcelona, Spain: a cross-sectional studyArkaitz Imaz, Mariana Camoez, Silvana Di Yacovo, et al.
Antiviral Therapy|March 9, 2005
Early virological failure with a combination of tenofovir, didanosine and efavirenzDaniel Podzamczer, Elena Ferrer, Josep Maria Gatell, et al.
Pageof 19